(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 July 2011 (28.07.2011)

PCT

(10) International Publication Number
WO 2011/089203 A1

(51) International Patent Classification:
A61K 38/18 (2006.01) *A61P 3/00* (2006.01)
A61K 38/26 (2006.01)

(21) International Application Number:
PCT/EP2011/050793

(22) International Filing Date:
21 January 2011 (21.01.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10305070.4 21 January 2010 (21.01.2010) EP

(71) Applicant *(for all designated States except US)*: **SANOFI-AVENTIS** [FR/FR]; 174 avenue de France, F-75013 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SOMMERFELD, Mark** [DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **SCHAEFER, Hans-Ludwig** [DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **BOSCHEINEN, Oliver** [DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **HABERMANN, Paul** [DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **RAO, Ercole** [DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **DREYER, Matthias** [DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE).

(74) Agent: **SCHNEIDER, Rudolf**; Sanofi-Aventis Deutschland GmbH, Patents Germany, Industriepark Höchst K 801, 65926 Frankfurt am Main (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: PHARMACEUTICAL COMPOSITION FOR TREATING A METABOLIC SYNDROME

Fig. 1



(57) **Abstract**: The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.

WO 2011/089203 A1